EA199900843A1 - Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b - Google Patents

Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b

Info

Publication number
EA199900843A1
EA199900843A1 EA199900843A EA199900843A EA199900843A1 EA 199900843 A1 EA199900843 A1 EA 199900843A1 EA 199900843 A EA199900843 A EA 199900843A EA 199900843 A EA199900843 A EA 199900843A EA 199900843 A1 EA199900843 A1 EA 199900843A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
selenolanecones
oxa
hepatitis
synthesis
Prior art date
Application number
EA199900843A
Other languages
English (en)
Other versions
EA001920B1 (ru
Inventor
Раймонд Ф. Шинази
Чунг К. Чу
Джинфа Ду
Original Assignee
Эмори Юниверсити
Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити, Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. filed Critical Эмори Юниверсити
Publication of EA199900843A1 publication Critical patent/EA199900843A1/ru
Publication of EA001920B1 publication Critical patent/EA001920B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Представляются способ и композиции для лечения инфекций ВИЧ, инфекций вируса гепатита-В или аномальной пролиферации клеток у человека и других животных, которые включают введение эффективного количества 1,3-оксаселеноланнуклеозида или его фармацевтически приемлемой соли, произвольно вместе с фармацевтически приемлемым носителем.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900843A 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b EA001920B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4126597P 1997-03-19 1997-03-19
PCT/US1998/005517 WO1998041522A1 (en) 1997-03-19 1998-03-19 Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides

Publications (2)

Publication Number Publication Date
EA199900843A1 true EA199900843A1 (ru) 2000-04-24
EA001920B1 EA001920B1 (ru) 2001-10-22

Family

ID=21915638

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900843A EA001920B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
EA200100494A EA005097B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200100494A EA005097B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b

Country Status (10)

Country Link
US (3) US6071922A (ru)
EP (1) EP0970078B1 (ru)
CN (1) CN1196701C (ru)
AT (1) ATE267198T1 (ru)
AU (1) AU739240B2 (ru)
CA (1) CA2287370C (ru)
DE (1) DE69823984T2 (ru)
EA (2) EA001920B1 (ru)
ES (1) ES2221164T3 (ru)
WO (1) WO1998041522A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408410T1 (de) * 1998-11-02 2008-10-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
NO20001904L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretanfilmer fremstilt ved elektrolytisk utfelling fra polyuretandispersjoner
NO20001903L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretan-filmer fremstilt fra polyuretan-dispersjoner
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
CA2788498C (en) 2001-03-01 2016-02-16 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US7785839B2 (en) * 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
WO2008030488A2 (en) 2006-09-06 2008-03-13 Med Institute, Inc. Stents with connectors and stabilizing biodegradable elements
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
KR101021294B1 (ko) * 2010-10-11 2011-03-11 공주대학교 산학협력단 신규한 셀레닐 메틸 우라실 화합물 및 이를 이용한 방사선 치료 증진제 및 의약 조성물
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
SG11201703588SA (en) * 2014-11-03 2017-05-30 Nicolai Vladimirovich Bovin Antimicrobial surface treatment

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPH02500017A (ja) * 1986-09-30 1990-01-11 ツアーンラートファブリーク、フリードリッヒスハーフェン、アクチエンゲゼルシャフト ブレーキ一体形の走行車伝動装置
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
ES2106772T3 (es) * 1989-12-20 1997-11-16 Biotech Australia Pty Ltd Variantes de pai-2.
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
AU662130B2 (en) * 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
CA2287370C (en) 2010-02-09
US6590107B1 (en) 2003-07-08
EA001920B1 (ru) 2001-10-22
EP0970078A1 (en) 2000-01-12
CA2287370A1 (en) 1998-09-24
ATE267198T1 (de) 2004-06-15
ES2221164T3 (es) 2004-12-16
US6071922A (en) 2000-06-06
EA200100494A1 (ru) 2001-10-22
CN1196701C (zh) 2005-04-13
AU739240B2 (en) 2001-10-04
AU6866598A (en) 1998-10-12
DE69823984D1 (de) 2004-06-24
US6197777B1 (en) 2001-03-06
EP0970078B1 (en) 2004-05-19
EA005097B1 (ru) 2004-10-28
CN1255132A (zh) 2000-05-31
WO1998041522A1 (en) 1998-09-24
DE69823984T2 (de) 2005-05-12
EA200100494A3 (ru) 2002-02-28

Similar Documents

Publication Publication Date Title
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
ES2134764T3 (es) Inhibidores de hiv proteasa.
DE69232649T2 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
FI912328A0 (fi) Peptidfoerening och dess framstaellning.
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
DE69104777T2 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
LV10054A (lv) Pretvirusu antibakterials savienojums un lietosanas metode
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
TR200101649T2 (tr) Piperazin türevleri.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
FI922044A0 (fi) Ny polypeptid och daerav framstaelld hiv-medicin.
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
RU94045248A (ru) Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
IT1225262B (it) Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
SE9602262D0 (sv) New use of derivatives of cystine
NO982151L (no) Hemoregulatoriske forbindelser
TW324663B (en) Interferon-ω(IFN-ω) as anti-HIV (human immune deficiency virus) agent
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU